ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO422

Indian Chronic Kidney Disease (ICKD) Study: A Prospective Cohort Study of CKD Patients in India

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 301 CKD: Risk Factors for Incidence and Progression

Authors

  • Yadav, Ashok Kumar, PGIMER, Chandigarh, India
  • Kumar, Vivek, Postgraduate Institute of Medical Education and Research, Chandigarh, India
  • Bhansali, Shobhit, PGIMER, Chandigarh, India
  • Modi, Gopesh K., Samarpan kidney Institute & Research Ctr., Bhopal, MadhyaPradesh, India
  • Gang, Sishir D., MULJIBHAI PATEL UROLOGICAL HOSPITAL, Nadiad, Gujarat, India
  • Prakash, Jai, Banaras Hindu University, Varanasi, India
  • Sircar, Dipankar, IPGMER,SSKM HOSPITAL, KOLKATA, India
  • Parameswaran, Sreejith, JIPMER, Ponidcherry, India
  • Prasad, Narayan, SGPGIMS CAMPUS, Lucknow, India
  • SAHAY, MANISHA, OSMANIA HOSPITAL, HYDERABAD, India
  • Varughese, Santosh, CMC, Vellore, India
  • Singh, Shivendra, Banaras Hindu University, Varanasi, India
  • Jha, Vivekanand, George Institute for Global Health, New Delhi, India
Background

The Indian Chronic Kidney Disease (ICKD) study (https://ickd.georgeinstitute.org.in/) is a multi-centric, prospective, observational cohort study of early stage CKD patients in India which will ascertain rate and factors influencing progression of CKD in India.

Methods

Adult subjects with mild to moderate CKD [estimated glomerular filtration rate (eGFR) 30-60 ml/min/1.73m2 or eGFR >60 ml/min/1.73m2 with proteinuria/albuminuria] are eligible for enrolment. Approximately 5000 subjects would be enrolled over 18 months. Time to 50% decline in eGFR, need of renal replacement therapy, CVD event or death are primary end points. A central bio-repository with serial biological samples is coupled with this cohort. Socio-economic aspects of treatment will also be studied.

Results

A total of 1567 subjects have been enrolled in the ICKD cohort till May 2017. The cause of CKD could not be ascertained in 25% of subjects. Chronic glomerulonephritis, diabetic kidney disease and chronic interstitial nephritis are causes for CKD in 16.5%, 18% and 17% of subjects, respectively. Tables 1 shows selective demographic characteristics of enrolled subjects. Majority are males belonging to rural areas with occupation exposure to sand, dust, chemicals or animals etc. 24% subjects had used alternative drugs and 10% had history suggestive of AKI in the past.

Conclusion

This is the first and most comprehensive description of an early stage CKD cohort from a developing country.

Funding

  • Government Support - Non-U.S.